Global Hepatitis B Therapeutic Drug 麻豆原创 Research Report 2024

Publication ID:

PB505251682

Publication Date:

May 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Treatment for chronic hepatitis B may include: Antiviral medications. Several antiviral medications 鈥� including entecavir (Baraclude),听tenofovir听(Viread),听lamivudine听(Epivir), adefovir (Hepsera) and telbivudine (Tyzeka) 鈥� can help fight the virus and slow its ability to damage your liver.
The global Hepatitis B Therapeutic Drug market was valued at US$ 2157 million in 2023 and is anticipated to reach US$ 3242.7 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hepatitis B Therapeutic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Therapeutic Drug.
Report Scope
The Hepatitis B Therapeutic Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis B Therapeutic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis B Therapeutic Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
GlaxoSmithKline
Bristol-Myers Squibb
Mitsubishi Tanabe Pharma
Johnson & Johnson
Roche
Gilead Sciences
Merck & Co. Inc.
Novartis
AbbVie
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis B Therapeutic Drug companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Hepatitis B Therapeutic Drug 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 Lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 麻豆原创 by Application
1.3.1 Global Hepatitis B Therapeutic Drug 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies & Drug Stores
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatitis B Therapeutic Drug 麻豆原创 Perspective (2019-2030)
2.2 Hepatitis B Therapeutic Drug Growth Trends by Region
2.2.1 Global Hepatitis B Therapeutic Drug 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hepatitis B Therapeutic Drug Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Hepatitis B Therapeutic Drug Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Hepatitis B Therapeutic Drug 麻豆原创 Dynamics
2.3.1 Hepatitis B Therapeutic Drug Industry Trends
2.3.2 Hepatitis B Therapeutic Drug 麻豆原创 Drivers
2.3.3 Hepatitis B Therapeutic Drug 麻豆原创 Challenges
2.3.4 Hepatitis B Therapeutic Drug 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatitis B Therapeutic Drug Players by Revenue
3.1.1 Global Top Hepatitis B Therapeutic Drug Players by Revenue (2019-2024)
3.1.2 Global Hepatitis B Therapeutic Drug Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Hepatitis B Therapeutic Drug 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hepatitis B Therapeutic Drug Revenue
3.4 Global Hepatitis B Therapeutic Drug 麻豆原创 Concentration Ratio
3.4.1 Global Hepatitis B Therapeutic Drug 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatitis B Therapeutic Drug Revenue in 2023
3.5 Hepatitis B Therapeutic Drug Key Players Head office and Area Served
3.6 Key Players Hepatitis B Therapeutic Drug Product Solution and Service
3.7 Date of Enter into Hepatitis B Therapeutic Drug 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Hepatitis B Therapeutic Drug Breakdown Data by Type
4.1 Global Hepatitis B Therapeutic Drug Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Hepatitis B Therapeutic Drug Forecasted 麻豆原创 Size by Type (2025-2030)
5 Hepatitis B Therapeutic Drug Breakdown Data by Application
5.1 Global Hepatitis B Therapeutic Drug Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Hepatitis B Therapeutic Drug Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Hepatitis B Therapeutic Drug 麻豆原创 Size (2019-2030)
6.2 North America Hepatitis B Therapeutic Drug 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hepatitis B Therapeutic Drug 麻豆原创 Size by Country (2019-2024)
6.4 North America Hepatitis B Therapeutic Drug 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hepatitis B Therapeutic Drug 麻豆原创 Size (2019-2030)
7.2 Europe Hepatitis B Therapeutic Drug 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hepatitis B Therapeutic Drug 麻豆原创 Size by Country (2019-2024)
7.4 Europe Hepatitis B Therapeutic Drug 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hepatitis B Therapeutic Drug 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Hepatitis B Therapeutic Drug 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hepatitis B Therapeutic Drug 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Hepatitis B Therapeutic Drug 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hepatitis B Therapeutic Drug 麻豆原创 Size (2019-2030)
9.2 Latin America Hepatitis B Therapeutic Drug 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hepatitis B Therapeutic Drug 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Hepatitis B Therapeutic Drug 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatitis B Therapeutic Drug 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Hepatitis B Therapeutic Drug 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hepatitis B Therapeutic Drug 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Hepatitis B Therapeutic Drug 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Detail
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Hepatitis B Therapeutic Drug Introduction
11.1.4 GlaxoSmithKline Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.1.5 GlaxoSmithKline Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Hepatitis B Therapeutic Drug Introduction
11.2.4 Bristol-Myers Squibb Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Mitsubishi Tanabe Pharma
11.3.1 Mitsubishi Tanabe Pharma Company Detail
11.3.2 Mitsubishi Tanabe Pharma Business Overview
11.3.3 Mitsubishi Tanabe Pharma Hepatitis B Therapeutic Drug Introduction
11.3.4 Mitsubishi Tanabe Pharma Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.3.5 Mitsubishi Tanabe Pharma Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Hepatitis B Therapeutic Drug Introduction
11.4.4 Johnson & Johnson Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Hepatitis B Therapeutic Drug Introduction
11.5.4 Roche Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Gilead Sciences
11.6.1 Gilead Sciences Company Detail
11.6.2 Gilead Sciences Business Overview
11.6.3 Gilead Sciences Hepatitis B Therapeutic Drug Introduction
11.6.4 Gilead Sciences Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.6.5 Gilead Sciences Recent Development
11.7 Merck & Co. Inc.
11.7.1 Merck & Co. Inc. Company Detail
11.7.2 Merck & Co. Inc. Business Overview
11.7.3 Merck & Co. Inc. Hepatitis B Therapeutic Drug Introduction
11.7.4 Merck & Co. Inc. Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.7.5 Merck & Co. Inc. Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Hepatitis B Therapeutic Drug Introduction
11.8.4 Novartis Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 AbbVie
11.9.1 AbbVie Company Detail
11.9.2 AbbVie Business Overview
11.9.3 AbbVie Hepatitis B Therapeutic Drug Introduction
11.9.4 AbbVie Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.9.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

GlaxoSmithKline
Bristol-Myers Squibb
Mitsubishi Tanabe Pharma
Johnson & Johnson
Roche
Gilead Sciences
Merck & Co. Inc.
Novartis
AbbVie

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.